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Induction of Stress Granule-Like Structures in Vesicular Stomatitis
Virus-Infected Cells
Phat X. Dinh, Lalit K. Beura,* Phani B. Das,* Debasis Panda,* Anshuman Das, Asit K. Pattnaik
School of Veterinary Medicine and Biomedical Sciences and the Nebraska Center for Virology, University of Nebraska—Lincoln, Lincoln, Nebraska, USA
Previous studies from our laboratory revealed that cellular poly(C) binding protein 2 (PCBP2) downregulates vesicular stomati-
tis virus (VSV) gene expression. We show here that VSV infection induces the formation of granular structures in the cytoplasm
containing cellular RNA-binding proteins, including PCBP2, T-cell-restricted intracellular antigen 1 (TIA1), and TIA1-related
protein (TIAR). Depletion of TIA1 via small interfering RNAs (siRNAs), but not depletion of TIAR, results in enhanced VSV
growth and gene expression. The VSV-induced granules appear to be similar to the stress granules (SGs) generated in cells trig-
gered by heat shock or oxidative stress but do not contain some of the bona fide SGmarkers, such as eukaryotic initiation factor
3 (eIF3) or eIF4A, or the processing body (PB) markers, such as mRNA-decapping enzyme 1A (DCP1a), and thus may not repre-
sent canonical SGs or PBs. Our results revealed that the VSV-induced granules, called SG-like structures here, contain the viral
replicative proteins and RNAs. The formation andmaintenance of the SG-like structures required viral replication and ongoing
protein synthesis, but an intact cytoskeletal network was not necessary. These results suggest that cells respond to VSV infection
by aggregating the antiviral proteins, such as PCBP2 and TIA1, to form SG-like structures. The functional significance of these
SG-like structures in VSV-infected cells is currently under investigation.
Mammalian cells respond to various environmental stresses,such as heat shock, amino acid deprivation, oxidative stress,
and hypoxia, as well as to viral infections, by inducing the forma-
tion of nonmembranous cytoplasmic structures called stress gran-
ules (SGs) (1–3). The SGs regulate mRNA metabolism by block-
ing the translation of housekeeping genes and facilitating the
synthesis of mostly stress response proteins (4). These responses
help the cells survive under stress conditions (1, 2). Several fami-
lies of viruses influence the formation of SGs in infected cells (5–
20). These viruses either induce or suppress SG formation to pro-
mote their replication. For example, orthoreoviruses induce SG
formation early in the infection cycle, which has been assumed to
be beneficial for virus replication (18). Poliovirus induces SG for-
mation early in infection, but the protein composition of these
SGs changes at later stages of infection due to the cleavage of
several SG marker proteins by the viral proteases (15, 19, 20). On
the other hand, several other viruses have been shown to interfere
with SG formation (5, 6, 8–10, 12, 16, 17, 19), and the results of
these studies emphasize the important role of SGs in the cellular
antiviral response. Individual protein components of the SGs or
the so-called “antiviral granules” (AVGs), such as T-cell-restricted
intracellular antigen 1 (TIA1) and RasGAP SH3 domain binding
protein 1 (G3BP1), have been found to inhibit the replication of a
number of viruses, indicating that not only the SGs but also the
individual components of the SGs may serve as antagonistic fac-
tors in viral replication processes (17, 19). Thus, SGs and/or AVGs
formed in response to viral infection may represent manifesta-
tions of interactions between host cells and viruses, a possibility
that is also supported by the observations that (i) Sendai virus
trailer RNA binds and sequesters TIA1-related protein (TIAR) in
order to reduce the virus-induced apoptosis mediated by TIAR
(21) and (ii) the interaction of TIA1/TIAR with the 3=-terminal
stem-loop of West Nile virus (WNV) minus-strand RNA sup-
presses the formation of SGs and processing bodies (PBs) to favor
virus replication (6).
Infection of TIA1-knockout murine embryonic fibroblasts
(MEFs) with vesicular stomatitis virus (VSV), Sindbis virus, her-
pes simplex virus 1, or vaccinia virus results in increased virus
growth, whereas WNV replication is suppressed in these cells (10),
indicating that TIA1 has both antiviral and proviral properties.
However, the mechanisms of TIA1 involvement in these functions
remain poorly understood. TIA1 is known to interact and colo-
calize with poly(C) binding protein 2 (PCBP2) in cytoplasmic SGs
(22). Since we have demonstrated previously that PCBP2 exerts
antiviral activity against VSV (23), it is possible that the inhibitory
activity of PCBP2 may be mediated through cooperation between
these cellular proteins and/or through the formation of SGs or
similar structures in infected cells.
VSV is an enveloped, nonsegmented, negative-stranded RNA
virus in the family Rhabdoviridae that initiates its infection cycle
by entering cells through receptor-mediated endocytosis, fol-
lowed by the delivery of its nucleocapsid (NC) template into the
cytoplasm. Viral genome transcription and replication occur in
the cytoplasm. Unlike those for many positive-stranded and dou-
ble-stranded RNA viruses, whose replication and transcription
usually occur in cytoplasmic factories or in association with mem-
branous organelles specifically induced in virus-infected cells (24–
26), the cytoplasmic sites for VSV replication are poorly charac-
terized. In VSV-infected cells, the viral replication proteins (N, P,
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and L) and nascently synthesized viral RNAs have been seen to be
colocalized to “granular structures” or “inclusions” in the cyto-
plasm (27, 28). Further, these granular structures or inclusions
have been suggested to be the sites of viral mRNA synthesis (27,
28). It has been proposed that these inclusions might reflect a
cellular response to the viral infection (28). While these granules
or inclusions contain viral proteins and RNA, their host cell pro-
tein composition, if any, has not been characterized yet. SG for-
mation has been demonstrated previously in cells infected with
Sendai virus (21) and, more recently, in respiratory syncytial vi-
rus-infected cells (7, 11). Whether the granules or inclusions seen
in VSV-infected cells are similar to the SGs observed in cells in-
fected with other viruses remains a matter of further investigation.
In this communication, we report the findings of our extended
studies on the role of PCBP2 in suppressing VSV infection and on
its relationship to TIA1 and TIAR. Our results show that TIA1 and
TIAR, together with PCBP2, are redistributed to cytoplasmic
VSV-induced SG-like structures that also contain the viral repli-
cation proteins and RNA. Like PCBP2, TIA1 displays an inhibi-
tory effect on viral gene expression and/or replication in VSV-
infected cells. The formation of SG-like structures containing
TIA1/PCBP2 is independent of the cellular microtubule and mi-
crofilament network and of cellular mRNA synthesis but requires
viral replication and ongoing protein synthesis. These SG-like
structures appear simultaneously with the phosphorylation of the
 subunit of eukaryotic initiation factor 2 (eIF2) and the host cell
translational shutoff, without a significant inhibitory effect on vi-
ral mRNA translation.
MATERIALS AND METHODS
Cell culture and reagents. Monolayer cultures of HeLa (ATCC catalog
no. CCL2), Huh7, MCF-7, and HEK293 cells were maintained in Dulbec-
co’s modified Eagle medium (DMEM) supplemented with 8% fetal bo-
vine serum (FBS) and the antibiotics penicillin (100 U/ml), kanamycin
(20 U/ml), and streptomycin (20 U/ml) (PKS). Baby hamster kidney
(BHK-21) cells were maintained in MEM supplemented with 5% FBS and
PKS. Immortalized murine embryonic fibroblasts (MEFs) from wild-type
(wt) and TIA1-knockout mice (29) were obtained from P. Anderson
(Harvard University) as well as M. Brinton (Georgia State University) and
were maintained as described previously (30). Sodium arsenite (SA), no-
codazole (Noc), cytochalasin D (CytoD), actinomycin D (ActD), 5-bro-
mouridine 5=-triphosphate sodium salt (BrUTP), cycloheximide (CHX),
and a protease inhibitor cocktail were obtained from Sigma-Aldrich and
were used at concentrations of 20 mM, 10 g/ml, 10 g/ml, 15 g/ml, 50
mM, 100g/ml, and 1, respectively. A 35S-labeled Met-Cys mixture for
protein labeling was obtained from Perkin-Elmer.
Viruses and VSV nucleocapsid (NC or RNP) preparation. Stocks of
wt VSV were prepared as described earlier (27, 31). VSVG virus and VSV
NCs (RNPs) were prepared as described previously (23).
Virus titration and infection. Virus titers were determined by plaque
assays on BHK-21 or HeLa cells. In each experiment, virus infection was
performed at a multiplicity of infection (MOI) of 1 or 0.01 PFU per cell,
except where indicated otherwise.
Antibodies. Anti-M (23H12) and anti-N (10G4) monoclonal anti-
bodies were kindly provided by D. Lyles. The mouse anti-VSV (serotype
Indiana) polyclonal antibody, the rabbit anti-P polyclonal antibody, and
the rabbit polyclonal antibody against the NH2-terminal region of the
VSV L protein have been described previously (32, 33). Antibodies against
actin (mouse monoclonal; Sc-47778), TIA1 (goat polyclonal; Sc-1751),
TIAR (goat polyclonal; Sc-1749), eIF3 (mouse monoclonal; Sc-137214),
and eIF4AII (mouse monoclonal; sc-137148) were purchased from Santa
Cruz Biotechnology, Inc. A rabbit polyclonal antibody against DCP1a
(ab47811) was purchased from Abcam. A mouse monoclonal antibody
against bromodeoxyuridine (BrdU) (clone BMC 9318) was obtained
from Roche Diagnostics. Anti-tubulin (clone DM 1A), anti-hemaggluti-
nin (anti-HA) monoclonal antibody HA-7 (H3663), horseradish perox-
idase-conjugated goat anti-rabbit immunoglobulin (IgG) (A6154),
horseradish peroxidase-conjugated goat anti-mouse IgG (A4416), and
horseradish peroxidase-conjugated rabbit anti-goat IgG (A4174) were
obtained from Sigma-Aldrich. Alexa Fluor 594-labeled donkey anti-goat
IgG (A-11058), Alexa Fluor 488-labeled donkey anti-mouse IgG (A-
21202), Alexa Fluor 488-labeled donkey anti-rabbit IgG (A-21206), Alexa
Fluor 647-labeled donkey anti-rabbit IgG (A-31573), Alexa Fluor 594-
labeled goat anti-mouse IgG (A-11005), and Alexa Fluor 488-labeled goat
anti-rabbit IgG (A-11034) were obtained from Invitrogen.
Plasmid constructs. Coding sequences of TIA1a (variant 2;
NM_022173.2) and TIARb (variant 1; NM_003252.3) were amplified us-
ing total RNA from HeLa cells and a LongAmp kit (New England Biolabs)
with the specific primers shown in Table 1. The PCR products were di-
gested with KpnI and EcoRI and were cloned into pcDHA (a plasmid
carrying an HA epitope tag) as described previously (23). The resulting
constructs express the inserted genes with an HA epitope at the N-termi-
nal ends of the proteins. The expression of the proteins can be driven by
either a cytomegalovirus (CMV) promoter or a T7 promoter located up-
stream of the coding sequences.
siRNA-mediated silencing. For depletion of TIA1 and TIAR, small
interfering RNAs (siRNAs) (pools of four different siRNAs) targeting
these genes (catalog no. L-013042-00-0005 and L-011405-00-0005, re-
spectively; Dharmacon) were transfected at a final concentration of 10 nM
(except where indicated otherwise) by following the protocol of reverse
transfection with Lipofectamine RNAiMax (Invitrogen) as recommended
by the manufacturer. At 24 h posttransfection (hpt), the transfection mix-
ture was replaced with DMEM containing 8% FBS and PKS, and the cells
were incubated further for 40 to 48 h to allow knockdown of the gene. A
nontargeting (NT) siRNA (catalog no. 1027281; Qiagen), which does not
target any of the known mammalian genes, was used as a control siRNA.
PlasmidDNAandNC (RNP) transfection.Plasmids were transfected
by using Lipofectamine 2000 (Invitrogen) according to the manufactur-
er’s instructions. At 4 hpt, the transfection mixture was replaced with
complete growth medium, and the culture was incubated for 40 to 44 h
before being used for an assay. Viral RNPs were also transfected by the
same procedure as that used for plasmid transfection and as described
previously (23).
WB. Western blotting (WB) and quantification of the protein bands
were performed as described previously (23). The following antibodies
were used: anti-M (dilution, 1:1,000 to 1:3,000), anti-actin (1:3,000 to
1:5,000), anti-TIA1 (1:500), anti-TIAR (1:500), and anti-HA (1:10,000).
Horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin
TABLE 1 Primers used in this study
Primer name Primer sequence (5= to 3=)a Use
TIA1-KpnI For ATATGGTACCATGGAGGACGAGATGCCCAAG Amplification and cloning of the TIA1a isoform
TIA1-EcoRI Rev ATATGAATTCTCACTGGGTTTCATACCCTGCC
TIAR-KpnI For ATATGGTACCATGATGGAAGACGACGGGCAG Amplification and cloning of the TIARb isoform
TIAR-EcoRI Rev ATATGAATTCTCACTGTGTTTGGTAACTTGCCATAC
a Underlined sequences show restriction enzyme sites.
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(IgG), horseradish peroxidase-conjugated goat anti-mouse IgG, and
horseradish peroxidase-conjugated rabbit anti-goat IgG, at dilutions of
1:500 to 10,000, were used as secondary antibodies.
Immunofluorescence (IF) microscopy. HeLa cells grown on glass
coverslips were infected with wt VSV at an MOI of 1 for the indicated time
(see figure legends), followed by fixation with methanol-acetone (1:1) for
15 min at30°C. After the cells were washed twice with phosphate-buff-
ered saline (PBS), they were stained with specific primary antibodies
against the proteins shown in each figure. The dilutions of the primary
antibodies used were as follows: 1:4,000 for anti-VSV N and anti-VSV L,
1:300 for anti-VSV P, 1:100 for anti-TIA1, anti-TIAR, and anti-eIF3,
1:3,000 for anti-HA, and 1:500 for anti-tubulin and anti-actin. The dilu-
tions of secondary antibodies were 1:300 to 1:500 for Alexa Fluor 594-
labeled donkey anti-goat IgG, 1:2,000 for Alexa Fluor 488-labeled donkey
anti-mouse IgG, 1:1,000 for Alexa Fluor 488-labeled donkey anti-rabbit
IgG, Alexa Fluor 647-labeled donkey anti-rabbit IgG, and Alexa Fluor
488-labeled goat anti-rabbit IgG, and 1:2,000 for Alexa Fluor 594-labeled
goat anti-mouse IgG. Images were obtained with an Olympus FV500/
IX81 inverted laser scanning confocal microscope.
qRT-PCR.The primers and probes for quantification of VSV P mRNA
and antigenome RNA by quantitative real-time PCR (qRT-PCR) were
used as described previously (34).
Metabolic labeling of proteins. Proteins in cells were labeled and de-
tected as described previously (35).
Statistical analysis. Statistical analyses were performed using the
MIXED procedure (SAS Institute, Inc., Cary, NC). The statistical model
included Treatment as a fixed effect. Data are presented as means stan-
dard errors of the means. A P value of0.05 was considered statistically
significant.
RESULTS
Cellular TIA1 downregulates VSV growth. Previously, we re-
ported that cellular PCBP2 inhibits VSV infection at the level of
viral gene expression (23). Recent studies have demonstrated that
PCBP2 is a component of SGs and that it interacts and colocalizes
with TIA1 in SGs induced by oxidative stress with agents such as
sodium arsenite (SA) (22). TIA1 and TIAR are well-known SG
markers (1, 2). The observations that MEFs from TIA1/ mice
support increased VSV growth (10) and that the putative SG in-
ducer thapsigargin inhibits VSV protein synthesis (36) led us to
hypothesize that the TIA1 and PCBP2 proteins may have related
functions in controlling VSV infection and may be involved in the
induction of SGs during VSV infection. To test this hypothesis, we
first examined the effects of depletion or overexpression of TIA1
on VSV growth in infected cells. Treatment of the cells with siRNA
for TIA1 resulted in	95% depletion of TIA1 protein (Fig. 1A). In
TIA1-depleted cells infected with VSV, virus growth was en-
hanced (	3-fold) over that in cells treated with the nontargeting
(NT) siRNA (Fig. 1B). Viral gene expression, examined by moni-
toring the levels of M protein in infected cells, was also increased
similarly upon TIA1 depletion (Fig. 1C).
To determine whether overexpression of TIA1 in HeLa cells
would affect VSV growth, we generated a plasmid encoding
HA-tagged TIA1 (variant a) under the control of the CMV promoter.
TIA1 variant a is the major isoform of TIA1 expressed in HeLa cells
(30). When HeLa cells were transfected with the plasmid encoding
HA-TIA1, the protein was readily detectable in the cells, and VSV
growth in these cells was inhibited	3-fold (Fig. 1D).
The availability of TIA1-knockout MEFs allowed us to further
examine the role of TIA1 in VSV replication. A previous study
(10) reported enhanced growth (up to 6-fold) of VSV in TIA1-
knockout MEFs. In contrast to the results of that study and those
from our siRNA-mediated depletion study, described above, we
found that VSV growth in TIA1/ MEFs was significantly re-
duced from that in wt MEFs. Viral growth kinetics analysis re-
vealed that VSV growth was dampened at least 5-fold in TIA1-
knockout MEFs, compared to that in wt MEFs, at all times
examined (Fig. 1E). This result was unexpected given the previous
report (10) as well as our studies with transient depletion of TIA1
by siRNA (Fig. 1B) but was consistently reproducible in at least
four repeat experiments using TIA1-knockout MEFs obtained
from both P. Anderson (clone 44) and M. Brinton (clone 43).
Strikingly, depletion of TIA1 from wt MEFs by siRNA resulted in
enhanced VSV growth (Fig. 1F), whereas ectopic expression of
HA-TIA1 in TIA1/ MEFs resulted in significant inhibition of
VSV growth (Fig. 1G). Taking these findings together, although
these studies point toward an inhibitory role of TIA1 in VSV
growth, there appears to be a discrepancy between the effects of
TIA1 when the protein is depleted transiently (siRNA mediated)
versus permanently (knockout).
Since TIA1 was found to inhibit VSV growth, we determined
whether TIAR, a TIA1-related protein, would also affect VSV
growth similarly. The results showed that depletion of TIAR by
siRNA did not enhance VSV growth significantly, although	80%
of the protein was depleted from the cells (Fig. 1H). Since TIAR
depletion resulted in increased TIA1 levels (Fig. 1H), consistent
with previous observations (10, 30), it is possible that the nonsig-
nificant increase in VSV growth in TIAR-depleted cells is due to
higher levels of TIA1 in these cells.
TIA1 exerts its effect on VSV growth at the level of viral gene
expression and/or genome replication. We next examined the
step(s) of VSV infection that is affected by TIA1. Since transfec-
tion of viral nucleocapsids (NCs) into cells bypasses the virus entry
steps and results in the expression of viral genes (23, 34), we ex-
amined the effect of TIA1 depletion on viral gene expression in
cells transfected with viral NCs. The level of viral M protein in
NC-transfected cells treated with siRNA specific for TIA1 was ap-
proximately 3-fold higher than that in NC-transfected cells
treated with NT siRNA (Fig. 2A, lanes 5 and 6). Furthermore, in
cells infected with VSVG (a virus that lacks the G gene and can-
not produce infectious virions, so that infection with this virus is
limited to a single cycle), the relative levels of VSV M expression
increased to a similar extent, approximately 3-fold, in TIA1
siRNA-treated cells compared to NT siRNA-treated cells (Fig. 2A,
lanes 3 and 4). Overall, the results show that TIA1 depletion re-
sults in a 3-fold increase in viral gene expression irrespective of the
use of a wt VSV, VSVG, or viral NC template, indicating that
the inhibitory effect of TIA1 on VSV infection takes place not at
the entry or assembly/budding step but likely at the viral gene
expression and/or replication step(s).
To more conclusively determine the effects of TIA1 on VSV gene
expression or replication, we used real-time PCR to assess the levels of
viral mRNA and antigenomic RNA in infected cells depleted of TIA1.
The results show that silencing of TIA1 protein led to increased levels
of both VSV mRNA (Fig. 2B) and antigenomic replicative RNA (Fig.
2C). The increase in mRNA and antigenomic RNA levels is similar to
that seen with the viral M protein levels (Fig. 2A). Thus, the results
further suggest that TIA1 restricts VSV infection at the level of viral
gene expression and/or replication.
VSV infection induces the formation of SG-like structures
that colocalize with viral replication proteins and RNA. Since
TIA1 is a common cytoplasmic SG marker (1), our observation
Dinh et al.
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that TIA1 inhibits VSV growth at gene expression steps prompted
us to investigate whether cytoplasmic SGs are induced in VSV-
infected cells. For this purpose, we infected cells with VSV and
performed an IF assay using antibodies to detect endogenous
TIA1 at different times postinfection. In mock-infected cells, the
majority of TIA1 was detected inside the nucleus (Fig. 3A, top
row). Following infection of cells with VSV, TIA1 was detected
readily in the cytoplasm at 3 h postinfection (hpi), with a concom-
itant decrease in the levels of proteins in the nucleus (data not
shown). By 7 hpi, the majority of TIA1 was seen in the cytoplasmic
granular structures (Fig. 3A, bottom row). Interestingly, the VSV
N protein was found to colocalize with these granular structures
(Fig. 3A, bottom row). The formation of these granules was read-
ily detected as early as 3 hpi, and the percentage of cells that con-
tained these granules continued to increase with time up to 7 hpi,
the last time point examined in these studies (see Fig. 7B). The
viral N protein was seen associated with these structures at all
times examined. Similar induction of TIA1-containing granules
was also observed in other cell lines, such as Huh7, MCF7, and
BHK-21, upon VSV infection (data not shown). Since these gran-
ular structures induced in VSV-infected cells did not contain
some of the canonical SG marker proteins (see below), we termed
these “SG-like structures.”
Previously, we reported that PCBP2 interacts with VSV P pro-
tein and inhibits VSV growth and gene expression (23). Thus, we
next determined whether PCBP2 is present in these TIA1-con-
taining SG-like structures. IF staining of VSV-infected cells ex-
pressing HA-tagged PCBP2 (HA-PCBP2) showed that HA-
PCBP2 colocalizes with endogenous TIA1 as well as with the viral
P protein in the SG-like structures (Fig. 3B). In mock-infected
cells, both HA-PCBP2 and TIA1 were detected mostly in the nu-
cleus, where they partially colocalized. These results indicate that
PCBP2 associates with TIA1 and VSV P protein in these virus-
induced SG-like structures.
In uninfected cells, TIA1 plays a key role in the induction of SG
formation and translational shutoff by replacing eIF2-GTP-
tRNAMet in the canonical preinitiation complex, leading to trans-
lational silencing (37). We found that in VSV-infected cells, TIA1
suppresses viral infection, colocalizes with the viral N and P pro-
teins, and is localized to the virus-induced SG-like structures. Pre-
FIG 1 TIA1 inhibits VSV growth. (A) Depletion of TIA1 by siRNA. HeLa cells were treated with siRNA targeting TIA1 at final concentrations of 0.1, 1, 5, 10, and
20 nM or with 20 nM nontargeting (NT) siRNA. TIA1 protein levels were determined by WB with an anti-TIA1 polyclonal antibody at 72 hpt. Actin served as
a loading control. (B) VSV growth is enhanced in TIA1-depleted cells. HeLa cells treated with NT siRNA or TIA1 siRNA at 10 nM for 68 to 72 h were infected with
VSV at an MOI of 0.01. Virus titers in the culture supernatants at the indicated hours postinfection were determined by a plaque assay. Statistical significance (P
value) was determined for virus titers at 12 and 16 hpi. (C) VSV M protein levels in TIA1-depleted cells. siRNA treatment and virus infection were performed as
described for panel B. VSV M protein and endogenous TIA1 in cell lysates prepared at 12 hpi were detected by WB with corresponding antibodies. (D) Ectopic
expression of TIA1 resulted in reduced levels of VSV growth. HeLa cells transfected with 1.5 g of an empty vector (EV) or an HA-TIA1-encoding plasmid for
48 h were infected with 0.01 MOI of VSV. At 12 hpi, culture supernatants were collected and analyzed by a plaque assay for infectious virus. Cell lysates were
examined by WB for HA-TIA1 expression. (E) Growth of VSV in wt and TIA1-knockout MEFs. MEFs were infected with VSV at an MOI of 1, and at the indicated
hours postinfection, culture supernatants were collected and titrated for infectious virus. Statistical significance was determined for virus titers at 12 and 18 hpi.
TIA1 protein levels were determined by WB with an anti-TIA1 polyclonal antibody. (F) Depletion of TIA1 by siRNA in wt MEFs results in enhanced growth of
VSV. Transfection of siRNA and virus infection were performed as described for panel B. Virus titers in the supernatants were determined at 12 hpi, and
endogenous TIA1 levels in the cells were determined by WB. (G) Ectopic expression of TIA1 in TIA1-knockout MEFs results in reduced virus growth. Plasmid
transfection, VSV infection, virus titration, and HA-TIA1 detection were carried out as described for panel D. (H) TIAR has no significant effect on VSV growth.
The conditions of siRNA transfection, virus infection, virus growth (at 16 hpi), and WB to detect TIAR and TIA1 are as described above for panels B and C. Error
bars represent the standard errors of the means from 3 independent experiments.
Inhibition of VSV Gene Expression by TIA1
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vious studies showed that VSV infection results in the formation
of cytoplasmic granular structures (27, 28) that contain not only
the viral N, P, and L replicative proteins but also viral RNA, and
these structures were described as cytoplasmic granules or repli-
cation and transcription inclusions (27, 28). Therefore, we next
determined whether the virus-induced SG-like structures contain
the other VSV replication proteins, such as the L protein, and viral
RNA. To address this question, we infected cells with VSV and, at
2 hpi, incubated the cells in actinomycin D (ActD) for 1 h prior to
the use of BrUTP for 4 h to label the newly synthesized viral RNA
as described previously (27). Under these conditions, cellular
DNA-dependent RNA synthesis is inhibited without any effect on
viral RNA-dependent RNA synthesis, and the newly synthesized
viral RNAs that have incorporated BrUTP can be specifically de-
tected with an antibody against bromodeoxyuridine (BrdU) (27).
IF staining of TIA1 and the VSV L protein or the BrUTP-labeled
viral RNA showed that TIA1 colocalized with the viral L protein
and the newly synthesized viral RNA (Fig. 3C). The TIAR protein
was also found to colocalize with VSV N, P, L, and RNA in the
same pattern as that observed for TIA1 (Fig. 3D and data not
shown). These results suggest that VSV infection induces SG-like
structures containing the viral replicative proteins and viral RNA.
VSV replication and ongoing protein synthesis are required
for the generation and maintenance of SG-like structures. The
observation that TIA1-containing SG-like structures increase in
number during the course of VSV infection led us to ask whether
the formation of these SG-like structures required ongoing viral
protein synthesis as well as viral replication. To address this ques-
tion, we infected cells with UV-inactivated VSV and performed IF
assays for the VSV N protein and TIA1 at 7 hpi. In cells infected
with UV-inactivated VSV, the majority of TIA1 was still present in
the nucleus, and cytoplasmic aggregates of TIA1 similar to SG-like
structures, typically seen in VSV-infected cells (Fig. 4A, middle
row), were not detected (Fig. 4A, bottom row). The absence of
detectable levels of N protein even at 7 hpi suggested that UV
treatment was sufficient to inactivate the virus and the induction
of SG-like structures. These results indicate that VSV replication is
critical for the formation of SG-like structures.
Since viral protein synthesis is necessary for VSV replication,
we next explored whether viral protein synthesis is required for
the maintenance of the SG-like structures in infected cells. Cyclo-
heximide (CHX), a translational inhibitor of protein synthesis,
was used in VSV-infected cells to examine the formation of SG-
like structures. CHX is also known to be an inhibitor of SG for-
mation, since it stalls the elongation of translation without allow-
ing the disassembly of the polysomes and thus prevents the
formation and/or maintenance of SGs (2). In agreement with pre-
vious observations (2, 17), the SGs induced by SA were disrupted
when cells were incubated with CHX for 2 h (Fig. 4B). Although
SG-like structures were readily seen in VSV-infected cells at 4 hpi
and had developed throughout the cells by 6 hpi, the number and
size of these structures were markedly reduced by incubation of
the infected cells with CHX at 4 hpi for an additional 1 or 2 h (Fig.
4C). The reductions in the size and number of SG-like structures
in the prolonged presence of CHX are concomitant with increased
translocation of TIA1 protein back to the nucleus (Fig. 4C), sug-
gesting that the induction and maintenance of VSV-induced SG-
like structures require active viral and/or cellular translation. This
hypothesis was further confirmed when we used siRNA targeting
VSV N mRNA to specifically inhibit translation, deplete the viral
N protein pool in infected cells, and block viral replication. Trans-
fection of N mRNA-specific siRNAs into cells inhibits VSV infec-
tion by	99% (34) and results in undetectable levels of viral pro-
teins and virus replication. Under these conditions, no formation
of TIA1-containing SG-like structures was detected at 5 hpi, al-
though at 7 hpi, a very small number of cells expressed low levels of
the viral N protein and exhibited a few small SG-like structures
(Fig. 4D, bottom two rows). These structures, however, could be
readily detected in infected cells transfected with a nontargeting
siRNA at 5 or 7 hpi (Fig. 4D, top two rows). These results suggest
that viral protein synthesis and viral replication are required for
the induction and development of TIA1-containing SG-like struc-
tures in VSV-infected cells.
VSV induced SG-like structure formation is not dependent
on a cellular microtubule or microfilament network. Cytoskel-
etal networks, particularly the microtubules and microfilaments,
have been shown to play different roles for the formation of SGs.
Microtubules are required for the induction, but not for the main-
tenance, of already formed SGs. In contrast, microfilaments are
dispensable for SG formation (38–41). Since microtubules and
microfilaments are important for VSV entry and the trafficking of
viral components in infected cells (27, 28, 42), we explored
whether microtubules and microfilaments are involved in the for-
mation of VSV-induced SG-like structures. In uninfected cells
treated with nocodazole (Noc), a drug known to inhibit microtu-
FIG 2 TIA1 negatively regulates VSV gene expression and/or replication. (A)
HeLa cells were transfected with 10 nM NT or TIA1 siRNA for 72 h. Then the
cells either were infected with VSV at an MOI of 0.01 for 12 h (lanes 1 and 2) or
with VSVG at an MOI of 0.5 for 8 h (lanes 3 and 4) or were supertransfected
for 6 h with viral NC prepared from VSV (lanes 5 and 6). Cell lysates corre-
sponding to equal amounts of total proteins were analyzed by WB with anti-
TIA1 and anti-M antibodies. Actin served as a loading control. (B and C) VSV
mRNA (B) and antigenomic RNA (C) levels in TIA1-depleted cells were de-
termined by qRT-PCR. The conditions of virus infection were the same as
those described for panel A, lanes 1 and 2. Values are means standard errors
of means for duplicate reactions from two independent experiments after nor-
malization to the values for the NT control.
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bule polymerization, complete depolymerization of microtubules
was observed after 2 h of treatment (Fig. 5A), and under these
conditions, SA-induced SG formation was inhibited, as reported
previously (39, 40). In cells treated with Noc for 2 h and subse-
quently infected with VSV for 7 h, SG-like structures containing
TIA1 could be detected readily, although they were somewhat less
numerous than those in control cells treated with dimethyl sulfox-
ide (DMSO) (Fig. 5B). The reduced number of SG-like structures
could be a result of reduced and/or delayed growth of VSV in the
presence of Noc (27, 28). These results indicate that VSV-induced
SG-like structures containing TIA1 are not dependent on a micro-
tubule network.
To examine the involvement of microfilaments in the forma-
tion of SG-like structures, cells were treated for 2 h with cytocha-
lasin D (CytoD) to inhibit the polymerization of actin before VSV
infection. Treatment of cells with CytoD for 2 h resulted in com-
plete disassembly of actin filaments (Fig. 5C). When cells treated
with CytoD were infected with VSV, the SG-like structures were
still formed, albeit at slightly reduced levels (Fig. 5D). The reduced
levels of SG-like structures can be ascribed to the documented
negative effects of actin depolymerization on VSV infection (42).
Overall, the results suggest that the formation of TIA1-con-
taining SG-like structures in VSV-infected cells does not require
intact cellular microtubules or microfilaments.
FIG 3 VSV infection induces the formation of SG-like structures. (A) VSV N protein colocalizes with SG-like structures containing cellular TIA1 protein. HeLa
cells grown on glass coverslips were either mock infected or infected with VSV at an MOI of 1. Coverslips were collected at 7 hpi and were immunostained for VSV
N and cellular TIA1. The secondary antibodies used were Alexa Fluor 594-labeled donkey anti-goat IgG for TIA1 (red) and Alexa Fluor 488-labeled donkey
anti-mouse IgG for VSV N (green). Nuclei were stained with 4=,6-diamidino-2-phenylindole (blue). (B) PCBP2 colocalizes with VSV-induced SG-like structures.
HeLa cells transfected with a plasmid carrying HA-PCBP2 for 48 h were infected with wt VSV at an MOI of 1. Coverslips containing VSV-infected or
mock-infected cells were processed for IF analysis with anti-HA (for HA-PCBP2), anti-VSV P, and anti-TIA1 antibodies at 7 hpi. The secondary antibodies used
were Alexa Fluor 594-labeled donkey anti-goat IgG for TIA1 (red), Alexa Fluor 488-labeled donkey anti-mouse IgG for HA-PCBP2 (green), and Alexa Fluor
647-labeled donkey anti-rabbit IgG for VSV P (purple). Nuclei were stained with 4=,6-diamidino-2-phenylindole. (C) VSV-induced SG-like structures contain
viral L protein and RNA. HeLa cells were infected with VSV at an MOI of 1. At 2 hpi, cells were treated with ActD, and incubation was continued for a further
5 h. The cells were then fixed and processed for IF to detect TIA1 protein (red) and VSV L protein (green). To detect viral RNA, cells similarly infected with VSV
were treated with ActD at 2 hpi for 1 h and were then transfected with BrUTP for 4 h in the presence of ActD. The cells were subjected to IF with antibodies against
BrdU to detect newly synthesized RNA (green) and TIA1 (red). Secondary antibodies were Alexa Fluor 594-labeled donkey anti-goat IgG for TIA1 (red), Alexa
Fluor 488-labeled donkey anti-mouse IgG for BrUTP (green), and Alexa Fluor 488-labeled donkey anti-rabbit IgG for VSV L protein (green). Nuclei were stained
with 4=,6-diamidino-2-phenylindole. (D) VSV N protein colocalizes with SG-like structures containing cellular TIAR protein. Experimental conditions were the
same as those described for panel A.
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Canonical SGs are distinct from the SG-like structures in-
duced by VSV and are not inhibited in VSV-infected cells. The
observations that (i) VSV infection induces the formation of SG-
like structures containing the reliable SG marker TIA1 and (ii) the
SG-like structures are not stable in infected cells treated with CHX
(Fig. 4C) suggest that the VSV-induced SG-like structures are a
form of SGs. However, the fact that the formation of these struc-
tures is not dependent on cellular transcription (Fig. 3D) or on a
microtubule or microfilament network (Fig. 5) raises an impor-
tant question: whether the SG-like structures and the authentic
SGs are distinct. To address this question, we used IF microscopy
to look for the presence of the cellular eIF3 and eIF4A proteins,
two authentic markers of SGs (1), in the VSV-induced SG-like
structures. Our results show that although a majority of the cellu-
lar TIA1 protein colocalized with the eIF3 subunit in SA-induced
SGs in the cytoplasm (Fig. 6A, middle row) and TIA1 colocalized
with VSV P protein in the SG-like structures (Fig. 6A, bottom
row), a significant proportion of the eIF3 subunit did not colo-
calize with TIA1 or VSV P protein in these virus-induced struc-
tures in the cytoplasm (Fig. 6A, bottom row). Similar results were
also obtained with eIF4A in VSV-infected cells (data not shown),
suggesting that the VSV-induced SG-like structures are likely not
the classical SGs generated in cells under stress conditions.
Many viruses, including influenza A virus, Sendai virus, Junin
virus, West Nile virus, dengue virus, orthoreovirus, picornavi-
ruses, and vaccinia viruses, inhibit SG formation in infected cells
(5, 6, 8, 12, 16, 17, 19, 21). In VSV-infected cells, we have observed
that the virus-induced SG-like structures containing TIA1/PCBP2
are not canonical SGs. Thus, it was of interest to determine
whether cells can form SGs induced by SA during VSV infection.
To examine this, we infected cells with VSV and then induced SG
formation by SA. We could readily observe that canonical SGs
(indicated by the authentic marker eIF3) formed at the same
level in VSV-infected cells as in mock-infected cells at various time
points postinfection. Figure 6B shows the formation of SGs in-
duced by SA treatment of VSV-infected cells at 7 hpi. SGs induced
by heat shock, as visualized by the eIF3 marker, also were not
affected by VSV infection (data not shown). Further, we examined
FIG 4 VSV replication and ongoing protein synthesis are required for the generation and maintenance of SG-like structures. (A) UV-inactivated VSV does not
induce SG-like structures. HeLa cells were infected with untreated (VSV Control) or UV-treated (UV-VSV) VSV at an MOI of 1 for 7 h. Cells were processed for
IF to detect the VSV N (green) and TIA1 (red) proteins. The secondary antibodies were the same as those described for Fig. 3A. Nuclei were stained with
4=,6-diamidino-2-phenylindole. (B) SGs induced by SA are disrupted by the protein synthesis inhibitor CHX. HeLa cells were treated with SA for 30 min and
subsequently were either left untreated (top) or treated with CHX (bottom) for another 2 h before processing for IF. TIA1 was immunostained in red, and nuclei
were stained with 4=,6-diamidino-2-phenylindole. (C) VSV-induced SG-like structure formation and maintenance require ongoing protein synthesis. HeLa cells
were infected with VSV as described in panel A above for 4 or 6 h before IF (top two rows) or were treated with CHX at 4 hpi for 1 or 2 h and were then processed
for IF (bottom two rows) to detect the VSV N and cellular TIA1 proteins. Staining with secondary antibodies and 4=,6-diamidino-2-phenylindole was carried out
as in the experiment for which results are shown in panel A. (D) Either SG-like structures are not formed, or their numbers are reduced and their formation
delayed, when VSV replication and viral protein synthesis are inhibited by siRNA targeting VSV N mRNA. HeLa cells were transfected either with NT siRNA (top
two rows) or with siRNA for VSV N mRNA (bottom two rows) for 72 h and were then infected with VSV at an MOI of 1. IF was performed at 5 and 7 hpi for VSV
N and TIA1 proteins. The secondary antibodies used in these experiments were the same as those described for Fig. 3A. Nuclei were stained with
4=,6-diamidino-2-phenylindole.
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the formation of cellular processing bodies (PBs), another type of
granule involved in RNA metabolism and known to function to-
gether with SGs in translational shutoff via mRNA sequestration
or mRNA degradation (1, 2). As shown by IF staining for mRNA-
decapping enzyme 1A (DCP1a) in the cytoplasm, PBs were not
affected by VSV infection (Fig. 6C). These results indicate that
VSV infection neither interferes with the physiological level of PBs
nor hampers SG formation in response to oxidative stress or heat
shock.
Viral protein synthesis is not significantly affected in the
presence of SG-like structures despite eIF2 phosphorylation.
eIF2 phosphorylation and translational shutoff are the putative
events concurrent with SG formation under stress conditions, in-
cluding virus infections (1, 37). Cellular protein synthesis has been
shown to be inhibited during VSV infection, while translation of
viral proteins continued in parallel with the increasing level of
eIF2 phosphorylation (36, 43), although induction of eIF2
phosphorylation before infection resulted in the inhibition of
both cellular and VSV protein synthesis (36). Therefore, we exam-
ined the relationship between the phosphorylation of eIF2, the
formation of VSV-induced SG-like structures, and the synthesis of
viral and cellular proteins. Our results show that the levels of phos-
phorylated eIF2 in infected cells increased steadily until 5 hpi
and remained at the same level thereafter (Fig. 7A and B). The
percentage of cells exhibiting SG-like structures increased steadily
with time after virus infection (Fig. 7B). Cellular protein synthesis
was inhibited with time after VSV infection, while viral protein
synthesis levels increased (Fig. 7A and B) in spite of increased
levels of phosphorylated eIF2 at different times postinfection.
These results suggest that the formation of VSV-induced SG-like
structures increased simultaneously with the phosphorylation of
eIF2 and the shutoff of cellular protein synthesis.
Since TIA1 is a translational silencer (44–46), we determined
whether TIA1 would affect the rate of viral protein synthesis in
infected cells. To this end, cells treated with NT siRNA or siRNA
specific for TIA1 were infected with VSV for 7 h, and viral protein
synthesis was monitored by pulse-labeling with [35S]Met-Cys for
10 min. The results showed that the rate of viral protein synthesis
was not significantly affected by TIA1 depletion in these cells (Fig.
7C). Although short pulse-labeling (10-min) studies failed to re-
veal significant differences in the rates of viral protein synthesis
between cells with or without TIA1, it is possible that viral tran-
scription, mRNA stability, protein stability, and/or viral replica-
tion could contribute to the increased levels of viral proteins de-
tected in TIA1-depleted cells at 12 hpi as shown in Fig. 1C and 2A.
DISCUSSION
Previously, we showed that the cellular protein PCBP2 interacts
with the VSV P protein and inhibits viral replication at the level of
gene expression (23). In the present work, we conducted studies to
understand how PCBP2 inhibits VSV replication. The rationale
for these studies was derived from the observations that (i) PCBP2
is a component of cellular SGs and PBs (2, 22); (ii) PCBP2 inter-
acts and colocalizes with TIA1 in SGs (22); and (iii) several viruses
have been shown to induce and/or interfere with the formation of
TIA1/TIAR-containing SGs (5, 6, 8, 9, 12, 16, 17, 19). We show
here that TIA1, but not TIAR, inhibits VSV growth at the level of
viral gene expression and/or replication. Following VSV infection,
TIA1 translocates from the nucleus to the cytoplasm and aggre-
gates into cytoplasmic granules similar to the SGs seen in the cy-
toplasm of cells under stress conditions. These granules also con-
tain the viral replication proteins and RNA as well as PCBP2. The
formation of these granules required viral replication and protein
synthesis but was independent of cellular microtubule and micro-
filament networks or cellular transcription. The VSV-induced
granules, termed “SG-like structures,” appear to be similar to
FIG 5 The formation of VSV-induced SG-like structures is not dependent on a cellular microtubule or microfilament network. (A and B) A microtubule
network is dispensable for the formation of VSV-induced SG-like structures. Cells were treated with DMSO (vehicle control) or Noc for 2 h before mock infection
(A) or infection with VSV at an MOI of 1 (B). Mock-infected cells treated with Noc were used for IF to detect tubulin (green) and TIA1 (red). VSV-infected cells
were harvested at 7 hpi (9 h after Noc treatment), and specific antibodies were used to detect VSV N (green) and TIA1 (red). (C and D) The formation of
VSV-induced SG-like structures does not require a microfilament network. Cells were treated with ethanol (vehicle control) or CytoD for 2 h before mock
infection (C) or infection with VSV at an MOI of 1 (D). Mock-infected cells treated with CytoD were used for IF to detect actin (green) and TIA1 (red).
VSV-infected cells were harvested at 7 hpi (9 h after CytoD treatment), and specific antibodies were used to detect VSV N (green) and TIA1 (red). The secondary
antibodies used in these experiments were Alexa Fluor 594-labeled donkey anti-goat IgG for TIA1 (red) and Alexa Fluor 488-labeled donkey anti-mouse IgG for
VSV N, tubulin, or actin (green).
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those described previously as cytoplasmic granules or transcrip-
tion and replication inclusions (27, 28). However, these studies
could not unequivocally rule out the possibility that viral RNA
synthesis occurred in the cytoplasm and some of the newly syn-
thesized RNAs quickly accumulated at these sites. Therefore, the
question of whether the cytoplasmic granules or inclusions repre-
sent the sites of viral RNA synthesis remains unresolved. The for-
mation of the inclusions may reflect the host cell’s response to
VSV infection (28). This cellular response may depend on the
synthesis of critical levels of viral proteins and/or RNA and their
interactions with host cell components. Although the host cell
proteins in these granules have not been identified, it is tempting
to speculate that the granules are similar to the SG-like structures
described here and may represent aggregation of translational si-
lencing as well as RNA-binding proteins, such as TIA1 and
PCBP2, that are involved in inhibiting viral gene expression. Since
both TIA1 and TIAR are apoptotic proteins (47, 48), it is likely that
sequestration of these molecules in SG-like structures in infected
cells positively impacts cell survival and virus replication.
Although the induction of SG-like structures in infected cells
required viral replication and protein synthesis, our inability to
detect such structures (data not shown) in cells infected with VSV
defective interfering particle-infected cells constitutively express-
ing the viral replication proteins (49) suggests that viral transcrip-
tion and/or threshold concentrations of the viral proteins and
RNAs are required for their formation. This interpretation is con-
sistent with the delayed appearance (3 hpi) of the structures in
infected cells, even though virus transcription/replication and
protein synthesis can be detected within the first hour of infection
(unpublished data).
Numerous viruses have been shown to either induce (11, 13,
15, 17, 18, 50) or suppress (6, 8, 12, 14, 51) SG formation in
infected cells. It appears that the induction or suppression of SGs
and of each of their component proteins plays divergent roles in
either facilitating or inhibiting virus infections. Infection with po-
liovirus results in early induction of SGs (15, 19, 20) that are also
maintained at later times of infection with compositionally differ-
ent cellular SG proteins (15, 20). Interestingly, the composition-
ally different SGs that appear late in poliovirus infection, termed
“pseudo-SGs,” contain mostly self-aggregated TIA1 and lack
many of the canonical SG components (20). A mutant vaccinia
virus lacking the double-stranded RNA-binding E3L protein in-
duces cytoplasmic antiviral granules (AVGs) that inhibit virus
replication (17). These AVGs, which are not generated in cells
infected with wt vaccinia virus, contain TIA1, G3BP, and other
RNA-binding proteins and restrict the replication of the E3L
mutant virus (17). On the other hand, hepatitis C virus (HCV)-
induced SGs contain not only factors required for HCV replica-
tion (Rck1) but also antiviral factors (PCBP2, G3BP1, TIAR,
Xrn1) (52). Thus, whether the SGs, AVGs, or pseudo-SGs are
generated by the host cells in response to virus infection or are
generated by the viral proteins and RNAs to facilitate or limit virus
infection remains an open question at this time. Nevertheless, it
appears that specific interactions between viral and cellular com-
ponents over multiple pathways through the recruitment of com-
mon and unique SG markers may be crucial for the formation of
these granular structures.
In the case of VSV, TIA1/TIAR and PCBP2, along with the viral
proteins and RNAs, were found to be localized to the SG-like
structures, whose induction was independent of the cellular mi-
crotubule or microfilament network. Unlike canonical SGs,
whose formation is dependent not only on the cytoskeletal net-
work but also on cellular transcription, the SG-like structures in
VSV-infected cells formed in the absence of cellular transcription
FIG 6 Canonical SGs are distinct from the SG-like structures induced by VSV.
(A) VSV-induced SG-like structures do not contain eIF3. HeLa cells were either
mock infected (top two rows) or infected with wt VSV at an MOI of 1 (bottom
row). Mock-infected cells were either left untreated () or treated with SA (
) for
30 min, after which the cells were processed for IF to detect TIA1 and eIF3. The
bottom row shows VSV-infected cells at 7 hpi, immunostained for P, TIA1, and
eIF3. The secondary antibodies used were Alexa Fluor 594-labeled donkey anti-
goat IgG for TIA1 (red), Alexa Fluor 488-labeled donkey anti-mouse IgG for eIF3
(green), and Alexa Fluor 647-labeled donkey anti-rabbit IgG for VSV P (purple).
(B) Canonical SGs are not inhibited in VSV-infected cells. HeLa cells were either
mock infected (top row) or infected with wt VSV at an MOI of 1, and at 7 hpi, cells
were further treated with SA for 30 min to induce SGs. Cells were immunostained
for VSV P and cellular eIF3. The secondary antibodies used here were Alexa Fluor
594-labeled goat anti-mouse IgG for eIF3 (red) and Alexa Fluor 488-labeled goat
anti-rabbit IgG for VSV P (green). (C) VSV infection does not interfere with the
formation of cellular PBs. HeLa cells were either mock infected or infected with
VSV at an MOI of 1, and at 7 hpi, cells were stained for VSV N and the cellular PB
marker DCP1a. The secondary antibodies used were Alexa Fluor 488-labeled goat
anti-mouse IgG for VSV N (green) and Alexa Fluor 594-labeled goat anti-rabbit
IgG for DCP1a (red).
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and were independent of the cytoskeleton. Additional studies will
be necessary to determine the mechanism of formation of the
SG-like structures in VSV-infected cells. VSV infection also did
not interfere with the formation of canonical SGs containing eIF3
or eIF4A induced by SA treatment, suggesting that the SG-like
structures induced in VSV-infected cells may have a unique cellu-
lar protein composition. Further work to identify the cellular pro-
teins that accumulate in these SG-like structures will be important
to determine the role played by these structures in the VSV infec-
tion cycle. The observations that (i) the SG-like structures are
distinct from canonical SGs, (ii) the TIA1 protein, which blocks
the translation of cellular mRNA in canonical SGs, did not inhibit
VSV mRNA translation in infected cells (Fig. 7C), and (iii) VSV
RNA synthesis is enhanced in TIA1-depleted cells suggest that
TIA1 downregulates VSV infection through a mechanism other
than translational suppression, its traditional role.
The involvement of eIF2 phosphorylation and the double-
stranded RNA-dependent protein kinase (protein kinase R
[PKR]) in the formation of VSV-induced SG-like structures has
not been examined directly, although the level of SG-like struc-
tures increased concomitantly with the level of eIF2 phosphory-
lation. It will be of interest to explore whether PKR, which is acti-
vated in VSV infection and restricts virus replication (53), or other
eIF2-specific kinases play any role in the induction of the SG-like
structures.
The observations that VSV replication is enhanced in cells
when TIA1 is depleted transiently (by siRNA treatment) (Fig. 1B)
but is inhibited in cells permanently depleted of TIA1 (knockout
MEFs) (Fig. 1E) appear paradoxical. However, since TIA1 is in-
volved in cellular gene expression, including translational sup-
pression (29, 44–46) and mRNA processing (54–57), it is possible
that the expression of a certain cellular gene(s) required for VSV
growth may have been permanently compromised in MEFs de-
rived from the knockout mouse. Alternatively, TIA1 depletion in
MEFs may have resulted in the activation of an antiviral gene(s) to
block VSV growth. In contrast to the knockout of TIA1 in MEFs,
transient depletion of TIA1 in HeLa cells may not have perma-
nently affected these cellular factors. Therefore, the true effects of
TIA1 on VSV growth could be discerned in transient depletion
experiments, whereas in cells stably depleted of the protein, the
combined effects of TIA1 depletion and its subsequent effects on
cellular proteins are observed. Such a contention is supported by
the fact that siRNA-mediated depletion of TIA1 from wt MEFs
resulted in increased VSV growth whereas ectopic expression of
the protein in TIA1-knockout MEFs led to inhibition of VSV
growth. Proteomic and transcriptomic analysis of wt and TIA1-
FIG 7 Viral protein synthesis remains unaffected by the formation of SG-like structures despite eIF2 phosphorylation. (A) Protein synthesis in VSV-infected
cells. Two sets of HeLa cells were infected with wt VSV at an MOI of 1. (Top) One set was pulse-labeled with [35S]Met-Cys for 10 min before lysis at 0, 2, 3, 4, 5,
6, and 7 hpi. The viral proteins and the sizes of molecular markers (in kilodaltons) are shown. (Bottom) The other set of cells was directly harvested at each time
point mentioned above for WB analysis with antibodies to detect eIF2 and its phosphorylated form (P-eIF2) as indicated. Actin served as a loading control.
(B) Quantitative analysis of VSV-induced SG-like structures, levels of viral and cellular protein synthesis, and phosphorylation of eIF2 (P-eIF2) at various
times postinfection. The levels of cellular and viral protein synthesis and of P-eIF2 were determined from the results shown in panel A, based on the intensity
of the bands in the gels, by using Quantity One software (Bio-Rad). The rate of cellular protein synthesis was determined by the radioactivity between the L and
G bands, the G and N bands, and the P and M bands. The total cellular protein level at 0 hpi was set at 100%. The rate of viral protein synthesis was determined
by quantification of the L, G, N, P, and M bands. The total viral protein level at 6 hpi was set at 100%. The rate of eIF2phosphorylation was determined by setting
the P-eIF2 level to 100% at 6 hpi. The percentage of infected cells (indicated by staining for the VSV N protein) containing SG-like structures was determined
by random examination of 150 cells from each experiment. Error bars represent the standard errors of the means from three independent experiments. (C)
Protein synthesis in VSV-infected cells depleted of TIA1. HeLa cells transfected with NT siRNA or TIA1 siRNA for 68 to 72 h were infected with wt VSV at an MOI
of 1. At 6 hpi, cells were pulse-labeled with [35S]Met-Cys for 10 min before lysis. Equal amounts of proteins were analyzed on a sodium dodecyl sulfate-
polyacrylamide gel by electrophoresis, and the labeled proteins were detected by fluorography. Viral proteins are identified on the right.
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knockout MEFs may reveal important clues for a better under-
standing of the role of TIA1 in VSV infection.
In summary, our studies presented here reveal that TIA1 in-
hibits VSV replication and colocalizes with PCBP2, another cellu-
lar protein shown previously (23) to inhibit VSV replication, to
form SG-like structures in infected cells. Studies to determine the
cellular protein composition of these SG-like structures and their
roles in VSV-infected cells are ongoing.
ACKNOWLEDGMENTS
We thank Y. Zhou and Terry Fangman (University of Nebraska—Lincoln
microscopy core facility) for help in fluorescence microscopy. We also
thank P. Anderson (Harvard University) and M. Brinton (Georgia State
University) for the kind gift of the immortalized MEFS from wt and TIA1
knockout mice. We appreciate the excellent assistance of Z. H. Gill in the
laboratory.
This work was supported in part by National Institutes of Health grant
R01 AI34956.
REFERENCES
1. Anderson P, Kedersha N. 2008. Stress granules: the Tao of RNA triage.
Trends Biochem. Sci. 33:141–150.
2. Buchan JR, Parker R. 2009. Eukaryotic stress granules: the ins and outs of
translation. Mol. Cell 36:932–941.
3. Thomas MG, Loschi M, Desbats MA, Boccaccio GL. 2011. RNA gran-
ules: the good, the bad and the ugly. Cell. Signal. 23:324 –334.
4. Nover L, Scharf KD, Neumann D. 1989. Cytoplasmic heat shock gran-
ules are formed from precursor particles and are associated with a specific
set of mRNAs. Mol. Cell. Biol. 9:1298 –1308.
5. Borghese F, Michiels T. 2011. The leader protein of cardioviruses inhibits
stress granule assembly. J. Virol. 85:9614 –9622.
6. Emara MM, Brinton MA. 2007. Interaction of TIA-1/TIAR with West
Nile and dengue virus products in infected cells interferes with stress gran-
ule formation and processing body assembly. Proc. Natl. Acad. Sci. U. S. A.
104:9041–9046.
7. Hanley LL, McGivern DR, Teng MN, Djang R, Collins PL, Fearns R.
2010. Roles of the respiratory syncytial virus trailer region: effects of mu-
tations on genome production and stress granule formation. Virology
406:241–252.
8. Khaperskyy DA, Hatchette TF, McCormick C. 2012. Influenza A virus
inhibits cytoplasmic stress granule formation. FASEB J. 26:1629 –1639.
9. Khong A, Jan E. 2011. Modulation of stress granules and P bodies during
dicistrovirus infection. J. Virol. 85:1439 –1451.
10. Li W, Li Y, Kedersha N, Anderson P, Emara M, Swiderek KM, Moreno
GT, BrintonMA. 2002. Cell proteins TIA-1 and TIAR interact with the 3=
stem-loop of the West Nile virus complementary minus-strand RNA and
facilitate virus replication. J. Virol. 76:11989 –12000.
11. Lindquist ME, Lifland AW, Utley TJ, Santangelo PJ, Crowe JE, Jr. 2010.
Respiratory syncytial virus induces host RNA stress granules to facilitate
viral replication. J. Virol. 84:12274 –12284.
12. Linero FN, Thomas MG, Boccaccio GL, Scolaro LA. 2011. Junin virus
infection impairs stress granule formation in Vero cells treated with ar-
senite via inhibition of eIF2 phosphorylation. J. Gen. Virol. 92:2889 –
2899.
13. McInerney GM, Kedersha NL, Kaufman RJ, Anderson P, Liljestrom P.
2005. Importance of eIF2 phosphorylation and stress granule assembly
in alphavirus translation regulation. Mol. Biol. Cell 16:3753–3763.
14. Montero H, Rojas M, Arias CF, Lopez S. 2008. Rotavirus infection
induces the phosphorylation of eIF2 but prevents the formation of stress
granules. J. Virol. 82:1496 –1504.
15. Piotrowska J, Hansen SJ, Park N, Jamka K, Sarnow P, Gustin KE. 2010.
Stable formation of compositionally unique stress granules in virus-
infected cells. J. Virol. 84:3654 –3665.
16. Qin Q, Carroll K, Hastings C, Miller CL. 2011. Mammalian orthoreo-
virus escape from host translational shutoff correlates with stress granule
disruption and is independent of eIF2 phosphorylation and PKR. J. Vi-
rol. 85:8798 – 8810.
17. Simpson-Holley M, Kedersha N, Dower K, Rubins KH, Anderson P,
Hensley LE, Connor JH. 2011. Formation of antiviral cytoplasmic gran-
ules during orthopoxvirus infection. J. Virol. 85:1581–1593.
18. Smith JA, Schmechel SC, Raghavan A, Abelson M, Reilly C, Katze MG,
Kaufman RJ, Bohjanen PR, Schiff LA. 2006. Reovirus induces and ben-
efits from an integrated cellular stress response. J. Virol. 80:2019 –2033.
19. White JP, Cardenas AM, Marissen WE, Lloyd RE. 2007. Inhibition of
cytoplasmic mRNA stress granule formation by a viral proteinase. Cell
Host Microbe 2:295–305.
20. White JP, Lloyd RE. 2011. Poliovirus unlinks TIA1 aggregation and
mRNA stress granule formation. J. Virol. 85:12442–12454.
21. Iseni F, Garcin D, Nishio M, Kedersha N, Anderson P, Kolakofsky D.
2002. Sendai virus trailer RNA binds TIAR, a cellular protein involved in
virus-induced apoptosis. EMBO J. 21:5141–5150.
22. Fujimura K, Kano F, Murata M. 2008. Identification of PCBP2, a facil-
itator of IRES-mediated translation, as a novel constituent of stress gran-
ules and processing bodies. RNA 14:425– 431.
23. Dinh PX, Beura LK, Panda D, Das A, Pattnaik AK. 2011. Antagonistic
effects of cellular poly(C) binding proteins on vesicular stomatitis virus
gene expression. J. Virol. 85:9459 –9471.
24. den Boon JA, Ahlquist P. 2010. Organelle-like membrane compartmen-
talization of positive-strand RNA virus replication factories. Annu. Rev.
Microbiol. 64:241–256.
25. Miller S, Krijnse-Locker J. 2008. Modification of intracellular membrane
structures for virus replication. Nat. Rev. Microbiol. 6:363–374.
26. Salonen A, Ahola T, Kaariainen L. 2005. Viral RNA replication in asso-
ciation with cellular membranes. Curr. Top. Microbiol. Immunol. 285:
139 –173.
27. Das SC, Nayak D, Zhou Y, Pattnaik AK. 2006. Visualization of intracel-
lular transport of vesicular stomatitis virus nucleocapsids in living cells. J.
Virol. 80:6368 – 6377.
28. Heinrich BS, Cureton DK, Rahmeh AA, Whelan SP. 2010. Protein
expression redirects vesicular stomatitis virus RNA synthesis to cytoplas-
mic inclusions. PLoS Pathog. 6:e1000958. doi:10.1371/journal.
ppat.1000958.
29. Piecyk M, Wax S, Beck AR, Kedersha N, Gupta M, Maritim B, Chen S,
Gueydan C, Kruys V, Streuli M, Anderson P. 2000. TIA-1 is a transla-
tional silencer that selectively regulates the expression of TNF-. EMBO J.
19:4154 – 4163.
30. Izquierdo JM, Valcarcel J. 2007. Two isoforms of the T-cell intracellular
antigen 1 (TIA-1) splicing factor display distinct splicing regulation activ-
ities. Control of TIA-1 isoform ratio by TIA-1-related protein. J. Biol.
Chem. 282:19410 –19417.
31. Das SC, Pattnaik AK. 2004. Phosphorylation of vesicular stomatitis virus
phosphoprotein P is indispensable for virus growth. J. Virol. 78:6420 –
6430.
32. Das SC, Pattnaik AK. 2005. Role of the hypervariable hinge region of
phosphoprotein P of vesicular stomatitis virus in viral RNA synthesis and
assembly of infectious virus particles. J. Virol. 79:8101– 8112.
33. Schubert M, Harmison GG, Richardson CD, Meier E. 1985. Expression
of a cDNA encoding a functional 241-kilodalton vesicular stomatitis virus
RNA polymerase. Proc. Natl. Acad. Sci. U. S. A. 82:7984 –7988.
34. Panda D, Das A, Dinh PX, Subramaniam S, Nayak D, Barrows NJ,
Pearson JL, Thompson J, Kelly DL, Ladunga I, Pattnaik AK. 2011. RNAi
screening reveals requirement for host cell secretory pathway in infection
by diverse families of negative-strand RNA viruses. Proc. Natl. Acad. Sci.
U. S. A. 108:19036 –19041.
35. Das PB, Dinh PX, Ansari IH, de Lima M, Osorio FA, Pattnaik AK. 2010.
The minor envelope glycoproteins GP2a and GP4 of porcine reproductive
and respiratory syndrome virus interact with the receptor CD163. J. Virol.
84:1731–1740.
36. Connor JH, Lyles DS. 2005. Inhibition of host and viral translation
during vesicular stomatitis virus infection. eIF2 is responsible for the in-
hibition of viral but not host translation. J. Biol. Chem. 280:13512–13519.
37. Anderson P, Kedersha N. 2002. Visibly stressed: the role of eIF2, TIA-1,
and stress granules in protein translation. Cell Stress Chaperones 7:213–
221.
38. Fujimura K, Katahira J, Kano F, Yoneda Y, Murata M. 2009. Micro-
scopic dissection of the process of stress granule assembly. Biochim. Bio-
phys. Acta 1793:1728 –1737.
39. Ivanov PA, Chudinova EM, Nadezhdina ES. 2003. Disruption of micro-
tubules inhibits cytoplasmic ribonucleoprotein stress granule formation.
Exp. Cell Res. 290:227–233.
40. Ivanov PA, Chudinova EM, Nadezhdina ES. 2003. RNP stress-granule
formation is inhibited by microtubule disruption. Cell Biol. Int. 27:207–
208.
Dinh et al.
382 jvi.asm.org Journal of Virology
  
41. Kwon S, Zhang Y, Matthias P. 2007. The deacetylase HDAC6 is a novel
critical component of stress granules involved in the stress response.
Genes Dev. 21:3381–3394.
42. Cureton DK, Massol RH, Whelan SP, Kirchhausen T. 2010. The length
of vesicular stomatitis virus particles dictates a need for actin assembly
during clathrin-dependent endocytosis. PLoS Pathog. 6:e1001127. doi:
10.1371/journal.ppat.1001127.
43. Krishnamoorthy J, Mounir Z, Raven JF, Koromilas AE. 2008. The eIF2
kinases inhibit vesicular stomatitis virus replication independently of
eIF2 phosphorylation. Cell Cycle 7:2346 –2351.
44. Dixon DA, Balch GC, Kedersha N, Anderson P, Zimmerman GA,
Beauchamp RD, Prescott SM. 2003. Regulation of cyclooxygenase-2
expression by the translational silencer TIA-1. J. Exp. Med. 198:475– 481.
45. Kawai T, Lal A, Yang X, Galban S, Mazan-Mamczarz K, Gorospe M.
2006. Translational control of cytochrome c by RNA-binding proteins
TIA-1 and HuR. Mol. Cell. Biol. 26:3295–3307.
46. Yu Q, Cok SJ, Zeng C, Morrison AR. 2003. Translational repression of
human matrix metalloproteinases-13 by an alternatively spliced form of
T-cell-restricted intracellular antigen-related protein (TIAR). J. Biol.
Chem. 278:1579 –1584.
47. Forch P, Valcarcel J. 2001. Molecular mechanisms of gene expression
regulation by the apoptosis-promoting protein TIA-1. Apoptosis 6:463–
468.
48. Kawakami A, Tian Q, Duan X, Streuli M, Schlossman SF, Anderson P.
1992. Identification and functional characterization of a TIA-1-related
nucleolysin. Proc. Natl. Acad. Sci. U. S. A. 89:8681– 8685.
49. Panda D, Dinh PX, Beura LK, Pattnaik AK. 2010. Induction of inter-
feron and interferon signaling pathways by replication of defective inter-
fering particle RNA in cells constitutively expressing vesicular stomatitis
virus replication proteins. J. Virol. 84:4826 – 4831.
50. Raaben M, Groot Koerkamp MJ, Rottier PJ, de Haan CA. 2007. Mouse
hepatitis coronavirus replication induces host translational shutoff and
mRNA decay, with concomitant formation of stress granules and process-
ing bodies. Cell. Microbiol. 9:2218 –2229.
51. Isler JA, Maguire TG, Alwine JC. 2005. Production of infectious human
cytomegalovirus virions is inhibited by drugs that disrupt calcium homeo-
stasis in the endoplasmic reticulum. J. Virol. 79:15388 –15397.
52. Ruggieri A, Dazert E, Metz P, Hofmann S, Bergeest JP, Mazur J,
Bankhead P, Hiet MS, Kallis S, Alvisi G, Samuel CE, Lohmann V,
Kaderali L, Rohr K, Frese M, Stoecklin G, Bartenschlager R. 2012.
Dynamic oscillation of translation and stress granule formation mark the
cellular response to virus infection. Cell Host Microbe 12:71– 85.
53. Balachandran S, Roberts PC, Brown LE, Truong H, Pattnaik AK,
Archer DR, Barber GN. 2000. Essential role for the dsRNA-dependent
protein kinase PKR in innate immunity to viral infection. Immunity 13:
129 –141.
54. Del Gatto-Konczak F, Bourgeois CF, Le Guiner C, Kister L, Gesnel MC,
Stevenin J, Breathnach R. 2000. The RNA-binding protein TIA-1 is a
novel mammalian splicing regulator acting through intron sequences ad-
jacent to a 5= splice site. Mol. Cell. Biol. 20:6287– 6299.
55. Forch P, Puig O, Martinez C, Seraphin B, Valcarcel J. 2002. The splicing
regulator TIA-1 interacts with U1-C to promote U1 snRNP recruitment to
5= splice sites. EMBO J. 21:6882– 6892.
56. Le Guiner C, Lejeune F, Galiana D, Kister L, Breathnach R, Stevenin J,
Del Gatto-Konczak F. 2001. TIA-1 and TIAR activate splicing of alterna-
tive exons with weak 5= splice sites followed by a U-rich stretch on their
own pre-mRNAs. J. Biol. Chem. 276:40638 – 40646.
57. Zuccato E, Buratti E, Stuani C, Baralle FE, Pagani F. 2004. An intronic
polypyrimidine-rich element downstream of the donor site modulates
cystic fibrosis transmembrane conductance regulator exon 9 alternative
splicing. J. Biol. Chem. 279:16980 –16988.
Inhibition of VSV Gene Expression by TIA1
January 2013 Volume 87 Number 1 jvi.asm.org 383
 
